NKTR Earnings Date & History
Nektar Therapeutics (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 7:19 PM ET
Nektar Therapeutics
Pharmaceuticals
- Next earnings date
- Wednesday, November 4, 2026
- Reporting session
- After Close
- EPS estimate
- $-1.57
- Revenue estimate
- $10.4M
NKTR earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Thursday, August 13, 2026 | Q2 2026 | $-2.02 | $-1.23 | +39.2% | $10.1M |
| Thursday, May 7, 2026 | Q1 2026 | $-1.63 | $-1.82 | -11.9% | $10.9M |
| Thursday, March 12, 2026 | Q4 2025 | $-2.52 | $-1.78 | +29.5% | $21.8M |
| Thursday, November 6, 2025 | Q3 2025 | $-2.74 | $-1.87 | +31.7% | $11.8M |
| Thursday, August 7, 2025 | Q2 2025 | $-3.10 | $-2.95 | +4.7% | $11.2M |
What the market is watching in NKTR's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next NKTR earnings date?
- Nektar Therapeutics is scheduled to report on Wednesday, November 4, 2026 (After Close). Dates can change until the company confirms them.
- Does NKTR report before or after the market?
- The next report is scheduled after close.
- What EPS is expected for NKTR?
- Consensus EPS for the upcoming quarter is $-1.57, on revenue of $10.4M.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
NKTR earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.